Firefire personal page - To The Moon

Firefire

Firefire

No personal profile

12Follow

2Followers

0Topic

0Badge

2021-07-23

Good!

Sorry, the original content has been removed

2021-07-30

Nice!

AMD: Still Growing, Still Undervalued

2021-07-16

Like

Sorry, the original content has been removed

2021-07-10

Useful info

Sorry, the original content has been removed

2021-07-16

Really?

Sorry, the original content has been removed

2021-07-12

Yes!

Sorry, the original content has been removed

2021-08-09

Great!

BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far

2021-07-15

Like!

Sorry, the original content has been removed

2021-07-12

[Smile]

Sorry, the original content has been removed

2021-08-02

Great news for some!

Sorry, the original content has been removed

2021-07-01

?

Sorry, the original content has been removed

2023-12-14

Great ariticle, would you like to share it?

@JC888:Tesla won't hit $300 due to EU labour strike & US incentive removal.

2021-07-28

Yes! Please!

Sorry, the original content has been removed

2021-07-23

Like

Sorry, the original content has been removed

2021-07-02

Great!

J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant

2021-07-01

Right!

Pinterest bans all weight loss ads

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4088082880945180","uuid":"4088082880945180","gmtCreate":1624984212449,"gmtModify":1625151652391,"name":"Firefire","pinyin":"firefire","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":12,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":251820422627376,"gmtCreate":1702523006643,"gmtModify":1702523010966,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/251820422627376","repostId":"250919295287336","repostType":1,"repost":{"id":250919295287336,"gmtCreate":1702267778562,"gmtModify":1702269188326,"author":{"id":"3570103090255456","authorId":"3570103090255456","name":"JC888","avatar":"https://community-static.tradeup.com/news/1f15eae4f682dc4cb91bfca455452752","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3570103090255456","authorIdStr":"3570103090255456"},"themes":[],"title":"Tesla won't hit $300 due to EU labour strike & US incentive removal.","htmlText":"The headwinds Tesla is encountering lately is gathering pace. I am referring to the labour strike in Europe. Sweden to be precise. “Surprised” by how little coverage there is in US media. Perhaps the media feels that: It is a small matter, unworthy of highlight and it will blow over soon. OR Everybody wants a christmas rally at Tesla, drive it up, plunder it profits before allowing reality to set it. I think there is a bit of truth in both of above reasonings. What is happening to Tesla in Europe? The Swedish labour groups have been taking industrial action against Tesla in a bid to get it to sign collective bargaining agreements with mechanics. (see above). The IF Metall union and Tesla Sweden have meet twice but failed to arrive at a compromised solution. Instead of trying to resolve the","listText":"The headwinds Tesla is encountering lately is gathering pace. I am referring to the labour strike in Europe. Sweden to be precise. “Surprised” by how little coverage there is in US media. Perhaps the media feels that: It is a small matter, unworthy of highlight and it will blow over soon. OR Everybody wants a christmas rally at Tesla, drive it up, plunder it profits before allowing reality to set it. I think there is a bit of truth in both of above reasonings. What is happening to Tesla in Europe? The Swedish labour groups have been taking industrial action against Tesla in a bid to get it to sign collective bargaining agreements with mechanics. (see above). The IF Metall union and Tesla Sweden have meet twice but failed to arrive at a compromised solution. Instead of trying to resolve the","text":"The headwinds Tesla is encountering lately is gathering pace. I am referring to the labour strike in Europe. Sweden to be precise. “Surprised” by how little coverage there is in US media. Perhaps the media feels that: It is a small matter, unworthy of highlight and it will blow over soon. OR Everybody wants a christmas rally at Tesla, drive it up, plunder it profits before allowing reality to set it. I think there is a bit of truth in both of above reasonings. What is happening to Tesla in Europe? The Swedish labour groups have been taking industrial action against Tesla in a bid to get it to sign collective bargaining agreements with mechanics. (see above). The IF Metall union and Tesla Sweden have meet twice but failed to arrive at a compromised solution. Instead of trying to resolve the","images":[{"img":"https://community-static.tradeup.com/news/9237132c92f6ca9d88693c198f0c90f9","width":"783","height":"151"},{"img":"https://community-static.tradeup.com/news/99695afd3c65c543d2e73fafda505047","width":"596","height":"132"},{"img":"https://community-static.tradeup.com/news/47756ef0dbb51f51d5abfab020fc5463","width":"729","height":"187"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/250919295287336","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":16,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898549392,"gmtCreate":1628513859816,"gmtModify":1703507338967,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898549392","repostId":"2158844506","repostType":4,"repost":{"id":"2158844506","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628508062,"share":"https://ttm.financial/m/news/2158844506?lang=en_US&edition=fundamental","pubTime":"2021-08-09 19:21","market":"us","language":"en","title":"BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2158844506","media":"Reuters","summary":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses o","content":"<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-09 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158844506","content_text":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.\nAstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.\nBased on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.\nThat includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804046624,"gmtCreate":1627913705968,"gmtModify":1703497798584,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great news for some!","listText":"Great news for some!","text":"Great news for some!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804046624","repostId":"1172320411","repostType":4,"isVote":1,"tweetType":1,"viewCount":1847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806231076,"gmtCreate":1627656781195,"gmtModify":1703494305608,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806231076","repostId":"1135561812","repostType":4,"repost":{"id":"1135561812","kind":"news","pubTimestamp":1627637430,"share":"https://ttm.financial/m/news/1135561812?lang=en_US&edition=fundamental","pubTime":"2021-07-30 17:30","market":"us","language":"en","title":"AMD: Still Growing, Still Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=1135561812","media":"seekingalpha","summary":"AMD's margin gains are driven by growing strength in end markets.AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors  and Radeon graphic cards. The uptick in g","content":"<p><b>Summary</b></p>\n<ul>\n <li>AMD's margin gains are driven by growing strength in end markets.</li>\n <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>\n <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>\n <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p>\n<p>AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p>\n<p><b>Why AMD is worth $120</b></p>\n<p>Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p>\n<p>I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p>\n<p>Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>Turning to cash flow.</p>\n<p>AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p>\n<p>AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p>\n<p><b>Challenges to my price target</b></p>\n<p>The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p>\n<p>Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p>\n<p><b>Final thoughts</b></p>\n<p>AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD: Still Growing, Still Undervalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD: Still Growing, Still Undervalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could...</p>\n\n<a href=\"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135561812","content_text":"Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.\nAMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.\n\nJay_Zynism/iStock via Getty Images\nAMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.\nWhy AMD is worth $120\nBefore I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.\nI expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.\nTurning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.\n(Source:AMD)\nThe most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.\n(Source:AMD)\nTurning to cash flow.\nAMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.\nAMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.\n(Source: Author)\n\n\n\n\n\nAMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.\n(Source:AMD)\nAMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.\n(Source: Author)\n\n\n\n\n\nNvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.\nChallenges to my price target\nThe biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.\nSoftening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.\nFinal thoughts\nAMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.","news_type":1,"symbols_score_info":{"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":1903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803394466,"gmtCreate":1627409446355,"gmtModify":1703489425147,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Yes! Please!","listText":"Yes! Please!","text":"Yes! Please!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803394466","repostId":"2154990778","repostType":4,"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175158088,"gmtCreate":1627015878344,"gmtModify":1703482506127,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175158088","repostId":"1113949436","repostType":4,"isVote":1,"tweetType":1,"viewCount":1807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175159011,"gmtCreate":1627015712233,"gmtModify":1703482501389,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/175159011","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":2101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170479141,"gmtCreate":1626448206483,"gmtModify":1703760460963,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/170479141","repostId":"1149577900","repostType":4,"isVote":1,"tweetType":1,"viewCount":2413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170444448,"gmtCreate":1626448111884,"gmtModify":1703760457357,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170444448","repostId":"1171115394","repostType":4,"isVote":1,"tweetType":1,"viewCount":1720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147582288,"gmtCreate":1626364233844,"gmtModify":1703758824505,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147582288","repostId":"2151154518","repostType":4,"isVote":1,"tweetType":1,"viewCount":1591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146624446,"gmtCreate":1626077807785,"gmtModify":1703752866012,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/146624446","repostId":"2150267773","repostType":4,"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146620428,"gmtCreate":1626077461264,"gmtModify":1703752854233,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146620428","repostId":"2150230102","repostType":4,"isVote":1,"tweetType":1,"viewCount":312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141774034,"gmtCreate":1625896011928,"gmtModify":1703750664079,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Useful info","listText":"Useful info","text":"Useful info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141774034","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156231716,"gmtCreate":1625223849435,"gmtModify":1703738708511,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/156231716","repostId":"1190296598","repostType":4,"repost":{"id":"1190296598","kind":"news","pubTimestamp":1625213296,"share":"https://ttm.financial/m/news/1190296598?lang=en_US&edition=fundamental","pubTime":"2021-07-02 16:08","market":"us","language":"en","title":"J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1190296598","media":"The Wall Street Journal","summary":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & J","content":"<blockquote>\n Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n</blockquote>\n<p>Johnson &amp; Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p>\n<p>In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&amp;J said Thursday.</p>\n<p>The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p>\n<p>How well the J&amp;J shot fares against the Delta variant has been closely watched by health authorities around the world.</p>\n<p>Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p>\n<p>The new findings “reinforce the ability of the Johnson &amp; Johnson Covid-19 vaccine to help protect the health of people globally,” said J&amp;J Chief Scientific Officer Paul Stoffels.</p>\n<p>J&amp;J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p>\n<p>J&amp;J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p>\n<p>The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p>\n<p>The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p>\n<p>Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p>\n<p>So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p>\n<p>Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p>\n<p>England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p>\n<p>J&amp;J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p>\n<p>J&amp;J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p>\n<p>Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p>\n<p>In its large, pivotal study, the J&amp;J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p>\n<p>Overall, however, it was highly effective in places where variants were spreading during the trial.</p>\n<p>J&amp;J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p>\n<p>The study looked at blood samples from eight people in the J&amp;J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p>\n<p>Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&amp;J vaccine.</p>\n<p>The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&amp;J said.</p>\n<p>The U.S. Food and Drug Administrationauthorized J&amp;J’s shotin February.</p>\n<p>In April, federal health authorities temporarily recommended pausing use of J&amp;J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p>\n<p>Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 16:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting ...</p>\n\n<a href=\"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190296598","content_text":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.\nIn laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.\nThe positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.\nHow well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.\nMany countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%\nThe new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.\nJ&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.\nJ&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.\nThe Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.\nThe variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.\nVaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.\nSo far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.\nSeparate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.\nEngland’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.\nJ&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.\nJ&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.\nProduction of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.\nIn its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.\nOverall, however, it was highly effective in places where variants were spreading during the trial.\nJ&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.\nThe study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.\nData on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.\nThe study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.\nThe U.S. Food and Drug Administrationauthorized J&J’s shotin February.\nIn April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.\nTheauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":538,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158296798,"gmtCreate":1625150071114,"gmtModify":1703737249222,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158296798","repostId":"1186720190","repostType":4,"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158205478,"gmtCreate":1625149852294,"gmtModify":1703737239289,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Right!","listText":"Right!","text":"Right!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158205478","repostId":"2148825736","repostType":4,"repost":{"id":"2148825736","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625145380,"share":"https://ttm.financial/m/news/2148825736?lang=en_US&edition=fundamental","pubTime":"2021-07-01 21:16","market":"us","language":"en","title":"Pinterest bans all weight loss ads","url":"https://stock-news.laohu8.com/highlight/detail?id=2148825736","media":"Reuters","summary":"July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads","content":"<p>July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday.</p>\n<p>The digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index <a href=\"https://laohu8.com/S/BMI\">$(BMI)$</a> or similar indexes.</p>\n<p>\"This stance makes Pinterest the only major platform to prohibit all weight loss ads. It's an expansion of our ad policies that have long prohibited body shaming and dangerous weight loss products or claims,\" the company said in a blog post on Thursday.</p>\n<p>Ads promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not \"focus on weight loss.\" The company said it had developed the policy with guidance from the National Eating Disorders Association.</p>\n<p>Pinterest's head of policy, Sarah Bromma, said in an interview that the rule change prioritized Pinterest users' \"emotional and mental health and wellbeing, especially those directly impacted by eating disorders or diet culture or body shaming.\"</p>\n<p>Pinterest, which has long grappled with combating pro-eating disorder content on its site and has since 2015 blocked such searches and directed users to expert organizations, already has rules against ads promoting weight loss pills or containing before-and-after weight-loss imagery.</p>\n<p>The company also said this week that its global head of inclusion and diversity, Tyi McCray, was leaving the company after less than a year. The move was first reported by Protocol.</p>\n<p>Pinterest, which went public in 2019, has faced controversies around diversity and inequality in the last year, including when two former policy team employees alleged racial discrimination in the workplace.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinterest bans all weight loss ads</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinterest bans all weight loss ads\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-01 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday.</p>\n<p>The digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index <a href=\"https://laohu8.com/S/BMI\">$(BMI)$</a> or similar indexes.</p>\n<p>\"This stance makes Pinterest the only major platform to prohibit all weight loss ads. It's an expansion of our ad policies that have long prohibited body shaming and dangerous weight loss products or claims,\" the company said in a blog post on Thursday.</p>\n<p>Ads promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not \"focus on weight loss.\" The company said it had developed the policy with guidance from the National Eating Disorders Association.</p>\n<p>Pinterest's head of policy, Sarah Bromma, said in an interview that the rule change prioritized Pinterest users' \"emotional and mental health and wellbeing, especially those directly impacted by eating disorders or diet culture or body shaming.\"</p>\n<p>Pinterest, which has long grappled with combating pro-eating disorder content on its site and has since 2015 blocked such searches and directed users to expert organizations, already has rules against ads promoting weight loss pills or containing before-and-after weight-loss imagery.</p>\n<p>The company also said this week that its global head of inclusion and diversity, Tyi McCray, was leaving the company after less than a year. The move was first reported by Protocol.</p>\n<p>Pinterest, which went public in 2019, has faced controversies around diversity and inequality in the last year, including when two former policy team employees alleged racial discrimination in the workplace.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PINS":"Pinterest, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148825736","content_text":"July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday.\nThe digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index $(BMI)$ or similar indexes.\n\"This stance makes Pinterest the only major platform to prohibit all weight loss ads. It's an expansion of our ad policies that have long prohibited body shaming and dangerous weight loss products or claims,\" the company said in a blog post on Thursday.\nAds promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not \"focus on weight loss.\" The company said it had developed the policy with guidance from the National Eating Disorders Association.\nPinterest's head of policy, Sarah Bromma, said in an interview that the rule change prioritized Pinterest users' \"emotional and mental health and wellbeing, especially those directly impacted by eating disorders or diet culture or body shaming.\"\nPinterest, which has long grappled with combating pro-eating disorder content on its site and has since 2015 blocked such searches and directed users to expert organizations, already has rules against ads promoting weight loss pills or containing before-and-after weight-loss imagery.\nThe company also said this week that its global head of inclusion and diversity, Tyi McCray, was leaving the company after less than a year. The move was first reported by Protocol.\nPinterest, which went public in 2019, has faced controversies around diversity and inequality in the last year, including when two former policy team employees alleged racial discrimination in the workplace.","news_type":1,"symbols_score_info":{"PINS":0.9}},"isVote":1,"tweetType":1,"viewCount":701,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":175159011,"gmtCreate":1627015712233,"gmtModify":1703482501389,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/175159011","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":2101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806231076,"gmtCreate":1627656781195,"gmtModify":1703494305608,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806231076","repostId":"1135561812","repostType":4,"repost":{"id":"1135561812","kind":"news","pubTimestamp":1627637430,"share":"https://ttm.financial/m/news/1135561812?lang=en_US&edition=fundamental","pubTime":"2021-07-30 17:30","market":"us","language":"en","title":"AMD: Still Growing, Still Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=1135561812","media":"seekingalpha","summary":"AMD's margin gains are driven by growing strength in end markets.AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors  and Radeon graphic cards. The uptick in g","content":"<p><b>Summary</b></p>\n<ul>\n <li>AMD's margin gains are driven by growing strength in end markets.</li>\n <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>\n <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>\n <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p>\n<p>AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p>\n<p><b>Why AMD is worth $120</b></p>\n<p>Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p>\n<p>I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p>\n<p>Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>Turning to cash flow.</p>\n<p>AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p>\n<p>AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p>\n<p>AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p>\n<table>\n <tbody>\n  <tr></tr>\n </tbody>\n</table>\n<p>Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p>\n<p><b>Challenges to my price target</b></p>\n<p>The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p>\n<p>Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p>\n<p><b>Final thoughts</b></p>\n<p>AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD: Still Growing, Still Undervalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD: Still Growing, Still Undervalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could...</p>\n\n<a href=\"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135561812","content_text":"Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.\nAMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.\n\nJay_Zynism/iStock via Getty Images\nAMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.\nWhy AMD is worth $120\nBefore I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.\nI expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.\nTurning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.\n(Source:AMD)\nThe most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.\n(Source:AMD)\nTurning to cash flow.\nAMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.\nAMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.\n(Source: Author)\n\n\n\n\n\nAMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.\n(Source:AMD)\nAMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.\n(Source: Author)\n\n\n\n\n\nNvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.\nChallenges to my price target\nThe biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.\nSoftening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.\nFinal thoughts\nAMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.","news_type":1,"symbols_score_info":{"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":1903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170479141,"gmtCreate":1626448206483,"gmtModify":1703760460963,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/170479141","repostId":"1149577900","repostType":4,"isVote":1,"tweetType":1,"viewCount":2413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141774034,"gmtCreate":1625896011928,"gmtModify":1703750664079,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Useful info","listText":"Useful info","text":"Useful info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141774034","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170444448,"gmtCreate":1626448111884,"gmtModify":1703760457357,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170444448","repostId":"1171115394","repostType":4,"isVote":1,"tweetType":1,"viewCount":1720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146624446,"gmtCreate":1626077807785,"gmtModify":1703752866012,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/146624446","repostId":"2150267773","repostType":4,"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898549392,"gmtCreate":1628513859816,"gmtModify":1703507338967,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898549392","repostId":"2158844506","repostType":4,"repost":{"id":"2158844506","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628508062,"share":"https://ttm.financial/m/news/2158844506?lang=en_US&edition=fundamental","pubTime":"2021-08-09 19:21","market":"us","language":"en","title":"BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2158844506","media":"Reuters","summary":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses o","content":"<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-09 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158844506","content_text":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.\nAstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.\nBased on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.\nThat includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147582288,"gmtCreate":1626364233844,"gmtModify":1703758824505,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147582288","repostId":"2151154518","repostType":4,"isVote":1,"tweetType":1,"viewCount":1591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146620428,"gmtCreate":1626077461264,"gmtModify":1703752854233,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146620428","repostId":"2150230102","repostType":4,"isVote":1,"tweetType":1,"viewCount":312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804046624,"gmtCreate":1627913705968,"gmtModify":1703497798584,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great news for some!","listText":"Great news for some!","text":"Great news for some!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804046624","repostId":"1172320411","repostType":4,"isVote":1,"tweetType":1,"viewCount":1847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158296798,"gmtCreate":1625150071114,"gmtModify":1703737249222,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158296798","repostId":"1186720190","repostType":4,"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":251820422627376,"gmtCreate":1702523006643,"gmtModify":1702523010966,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/251820422627376","repostId":"250919295287336","repostType":1,"repost":{"id":250919295287336,"gmtCreate":1702267778562,"gmtModify":1702269188326,"author":{"id":"3570103090255456","authorId":"3570103090255456","name":"JC888","avatar":"https://community-static.tradeup.com/news/1f15eae4f682dc4cb91bfca455452752","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3570103090255456","authorIdStr":"3570103090255456"},"themes":[],"title":"Tesla won't hit $300 due to EU labour strike & US incentive removal.","htmlText":"The headwinds Tesla is encountering lately is gathering pace. I am referring to the labour strike in Europe. Sweden to be precise. “Surprised” by how little coverage there is in US media. Perhaps the media feels that: It is a small matter, unworthy of highlight and it will blow over soon. OR Everybody wants a christmas rally at Tesla, drive it up, plunder it profits before allowing reality to set it. I think there is a bit of truth in both of above reasonings. What is happening to Tesla in Europe? The Swedish labour groups have been taking industrial action against Tesla in a bid to get it to sign collective bargaining agreements with mechanics. (see above). The IF Metall union and Tesla Sweden have meet twice but failed to arrive at a compromised solution. Instead of trying to resolve the","listText":"The headwinds Tesla is encountering lately is gathering pace. I am referring to the labour strike in Europe. Sweden to be precise. “Surprised” by how little coverage there is in US media. Perhaps the media feels that: It is a small matter, unworthy of highlight and it will blow over soon. OR Everybody wants a christmas rally at Tesla, drive it up, plunder it profits before allowing reality to set it. I think there is a bit of truth in both of above reasonings. What is happening to Tesla in Europe? The Swedish labour groups have been taking industrial action against Tesla in a bid to get it to sign collective bargaining agreements with mechanics. (see above). The IF Metall union and Tesla Sweden have meet twice but failed to arrive at a compromised solution. Instead of trying to resolve the","text":"The headwinds Tesla is encountering lately is gathering pace. I am referring to the labour strike in Europe. Sweden to be precise. “Surprised” by how little coverage there is in US media. Perhaps the media feels that: It is a small matter, unworthy of highlight and it will blow over soon. OR Everybody wants a christmas rally at Tesla, drive it up, plunder it profits before allowing reality to set it. I think there is a bit of truth in both of above reasonings. What is happening to Tesla in Europe? The Swedish labour groups have been taking industrial action against Tesla in a bid to get it to sign collective bargaining agreements with mechanics. (see above). The IF Metall union and Tesla Sweden have meet twice but failed to arrive at a compromised solution. Instead of trying to resolve the","images":[{"img":"https://community-static.tradeup.com/news/9237132c92f6ca9d88693c198f0c90f9","width":"783","height":"151"},{"img":"https://community-static.tradeup.com/news/99695afd3c65c543d2e73fafda505047","width":"596","height":"132"},{"img":"https://community-static.tradeup.com/news/47756ef0dbb51f51d5abfab020fc5463","width":"729","height":"187"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/250919295287336","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":16,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803394466,"gmtCreate":1627409446355,"gmtModify":1703489425147,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Yes! Please!","listText":"Yes! Please!","text":"Yes! Please!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803394466","repostId":"2154990778","repostType":4,"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175158088,"gmtCreate":1627015878344,"gmtModify":1703482506127,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175158088","repostId":"1113949436","repostType":4,"isVote":1,"tweetType":1,"viewCount":1807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156231716,"gmtCreate":1625223849435,"gmtModify":1703738708511,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/156231716","repostId":"1190296598","repostType":4,"repost":{"id":"1190296598","kind":"news","pubTimestamp":1625213296,"share":"https://ttm.financial/m/news/1190296598?lang=en_US&edition=fundamental","pubTime":"2021-07-02 16:08","market":"us","language":"en","title":"J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1190296598","media":"The Wall Street Journal","summary":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & J","content":"<blockquote>\n Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n</blockquote>\n<p>Johnson &amp; Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p>\n<p>In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&amp;J said Thursday.</p>\n<p>The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p>\n<p>How well the J&amp;J shot fares against the Delta variant has been closely watched by health authorities around the world.</p>\n<p>Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p>\n<p>The new findings “reinforce the ability of the Johnson &amp; Johnson Covid-19 vaccine to help protect the health of people globally,” said J&amp;J Chief Scientific Officer Paul Stoffels.</p>\n<p>J&amp;J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p>\n<p>J&amp;J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p>\n<p>The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p>\n<p>The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p>\n<p>Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p>\n<p>So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p>\n<p>Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p>\n<p>England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p>\n<p>J&amp;J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p>\n<p>J&amp;J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p>\n<p>Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p>\n<p>In its large, pivotal study, the J&amp;J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p>\n<p>Overall, however, it was highly effective in places where variants were spreading during the trial.</p>\n<p>J&amp;J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p>\n<p>The study looked at blood samples from eight people in the J&amp;J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p>\n<p>Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&amp;J vaccine.</p>\n<p>The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&amp;J said.</p>\n<p>The U.S. Food and Drug Administrationauthorized J&amp;J’s shotin February.</p>\n<p>In April, federal health authorities temporarily recommended pausing use of J&amp;J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p>\n<p>Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 16:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting ...</p>\n\n<a href=\"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190296598","content_text":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.\nIn laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.\nThe positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.\nHow well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.\nMany countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%\nThe new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.\nJ&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.\nJ&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.\nThe Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.\nThe variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.\nVaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.\nSo far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.\nSeparate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.\nEngland’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.\nJ&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.\nJ&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.\nProduction of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.\nIn its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.\nOverall, however, it was highly effective in places where variants were spreading during the trial.\nJ&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.\nThe study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.\nData on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.\nThe study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.\nThe U.S. Food and Drug Administrationauthorized J&J’s shotin February.\nIn April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.\nTheauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":538,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158205478,"gmtCreate":1625149852294,"gmtModify":1703737239289,"author":{"id":"4088082880945180","authorId":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088082880945180","authorIdStr":"4088082880945180"},"themes":[],"htmlText":"Right!","listText":"Right!","text":"Right!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158205478","repostId":"2148825736","repostType":4,"repost":{"id":"2148825736","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625145380,"share":"https://ttm.financial/m/news/2148825736?lang=en_US&edition=fundamental","pubTime":"2021-07-01 21:16","market":"us","language":"en","title":"Pinterest bans all weight loss ads","url":"https://stock-news.laohu8.com/highlight/detail?id=2148825736","media":"Reuters","summary":"July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads","content":"<p>July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday.</p>\n<p>The digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index <a href=\"https://laohu8.com/S/BMI\">$(BMI)$</a> or similar indexes.</p>\n<p>\"This stance makes Pinterest the only major platform to prohibit all weight loss ads. It's an expansion of our ad policies that have long prohibited body shaming and dangerous weight loss products or claims,\" the company said in a blog post on Thursday.</p>\n<p>Ads promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not \"focus on weight loss.\" The company said it had developed the policy with guidance from the National Eating Disorders Association.</p>\n<p>Pinterest's head of policy, Sarah Bromma, said in an interview that the rule change prioritized Pinterest users' \"emotional and mental health and wellbeing, especially those directly impacted by eating disorders or diet culture or body shaming.\"</p>\n<p>Pinterest, which has long grappled with combating pro-eating disorder content on its site and has since 2015 blocked such searches and directed users to expert organizations, already has rules against ads promoting weight loss pills or containing before-and-after weight-loss imagery.</p>\n<p>The company also said this week that its global head of inclusion and diversity, Tyi McCray, was leaving the company after less than a year. The move was first reported by Protocol.</p>\n<p>Pinterest, which went public in 2019, has faced controversies around diversity and inequality in the last year, including when two former policy team employees alleged racial discrimination in the workplace.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinterest bans all weight loss ads</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinterest bans all weight loss ads\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-01 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday.</p>\n<p>The digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index <a href=\"https://laohu8.com/S/BMI\">$(BMI)$</a> or similar indexes.</p>\n<p>\"This stance makes Pinterest the only major platform to prohibit all weight loss ads. It's an expansion of our ad policies that have long prohibited body shaming and dangerous weight loss products or claims,\" the company said in a blog post on Thursday.</p>\n<p>Ads promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not \"focus on weight loss.\" The company said it had developed the policy with guidance from the National Eating Disorders Association.</p>\n<p>Pinterest's head of policy, Sarah Bromma, said in an interview that the rule change prioritized Pinterest users' \"emotional and mental health and wellbeing, especially those directly impacted by eating disorders or diet culture or body shaming.\"</p>\n<p>Pinterest, which has long grappled with combating pro-eating disorder content on its site and has since 2015 blocked such searches and directed users to expert organizations, already has rules against ads promoting weight loss pills or containing before-and-after weight-loss imagery.</p>\n<p>The company also said this week that its global head of inclusion and diversity, Tyi McCray, was leaving the company after less than a year. The move was first reported by Protocol.</p>\n<p>Pinterest, which went public in 2019, has faced controversies around diversity and inequality in the last year, including when two former policy team employees alleged racial discrimination in the workplace.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PINS":"Pinterest, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148825736","content_text":"July 1 (Reuters) - Pinterest is banning all ads with weight loss language and imagery, including ads that idealize or denigrate certain body types, it said on Thursday.\nThe digital pinboard site said it would also not allow ads with testimonials about weight loss or weight loss products, or ads referencing Body Mass Index $(BMI)$ or similar indexes.\n\"This stance makes Pinterest the only major platform to prohibit all weight loss ads. It's an expansion of our ad policies that have long prohibited body shaming and dangerous weight loss products or claims,\" the company said in a blog post on Thursday.\nAds promoting healthy lifestyles, habits or fitness services and products are still allowed on the platform if they do not \"focus on weight loss.\" The company said it had developed the policy with guidance from the National Eating Disorders Association.\nPinterest's head of policy, Sarah Bromma, said in an interview that the rule change prioritized Pinterest users' \"emotional and mental health and wellbeing, especially those directly impacted by eating disorders or diet culture or body shaming.\"\nPinterest, which has long grappled with combating pro-eating disorder content on its site and has since 2015 blocked such searches and directed users to expert organizations, already has rules against ads promoting weight loss pills or containing before-and-after weight-loss imagery.\nThe company also said this week that its global head of inclusion and diversity, Tyi McCray, was leaving the company after less than a year. The move was first reported by Protocol.\nPinterest, which went public in 2019, has faced controversies around diversity and inequality in the last year, including when two former policy team employees alleged racial discrimination in the workplace.","news_type":1,"symbols_score_info":{"PINS":0.9}},"isVote":1,"tweetType":1,"viewCount":701,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}